Shares of Catalyst Biosciences (NASDAQ: CBIO) are 15% higher this morning on news that a positive opinion recommending orphan medicinal product designation has been issued by the European Medicines Agency Committee (EMA) for Orphan Medicinal Products (COMP) regarding Catalyst’s CB 2679d for the treatment of hemophilia B. The clinical-stage biopharmaceutical company’s highly potent next-generation coagulation Factor IX variant demonstrated potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Currently approved therapies rely on numerous intravenous infusions. “Obtaining orphan drug designation is an important part of our regulatory approval strategy for CB 2679d, and the receipt of the positive COMP opinion puts us one step closer to this goal,” Catalyst president and CEO Nassim Usman, Ph.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/1iAwB
About Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, visit www.catalystbiosciences.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment